German biotech Immatics eyes pivotal Phase 3 readout after promising uveal melanoma cell therapy results

Immatics, a German biotech founded 26 years ago, is focusing on cancer immunotherapy. Its lead candidate is an experimental cell therapy targeting uveal melanoma.

Early Phase 1 data in 16 patients showed tumor shrinkage in all participants, a striking result for this rare eye cancer. The investigators suggested the approach could be extended to harder-to-treat cancers such as pancreatic and ovarian.

The company now awaits Phase 3 trial results, which will determine whether the therapy can move toward regulatory approval. Success would be a major milestone for Immatics and could broaden immunotherapy options.